Pfizer, Inc. · NYSE:PFE

Pfizer — ASCO 2008 Analyst Briefing

71 slides from Pfizer's conference presentation, Jun 2, 2008

  1. Slide 1: ASCO 2008 Analyst Briefing

    ASCO 2008 A l tB Analyst Briefing i fi June 2, 2008

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information  Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in

  3. Slide 3: Pfizer's Emerging Leadership in Oncology

    Pfizer’s Emerging Leadership in Oncology Alison Ayers World Wide Commercial Leader

  4. Slide 4: Pfizer Oncology Leadership Team

    Pfizer Oncology Leadership Team Garry Nicholson Senior Vice President/General Manager Alison Ayers Charles Baum Craig Eagle Pat Andrews WW Commercial WW Development WW Medical Leader US General Manager Leader Leader Pfizer Regional Pfizer Regional Commercial Operations Medical Operations 4

  5. Slide 5: Pfizer Therapeutic Area Priorities

    Pfizer Therapeutic Area Priorities Invest to Win First or High Market High Best in Class Growth Unmet Need     Oncology  Pain  Immunology/Inflammation  Diabetes/Obesity  Alzheimer’s Disease  Schizophrenia 5

  6. Slide 6: Oncology R&D Achievements

    Oncology R&D Achievements Increase in number of oncology R&D projects in past five years 400% Ongoing or planned oncology studies 232 Oncology compounds in clinical development 22 Research budget dedicated to oncology 22% 6

  7. Slide 7: Pfizer's Four Oncology Research Platforms

    Pfizer’s Four Oncology Research Platforms ANTI- IMMUNOTHERAPY ANGIOGENESIS Reawakens immune Blocks growth of system tumor blood vessels SIGNAL CYTOTOXIC/ TRANSDUCTION POTENTIATORS INHIBITORS Exploit defects Blocks cancer in repair and growth signals cycle cells 7

  8. Slide 8: Advances in the Oncology Pipeline in the Clinic

    Advances in the Oncology Pipeline in the Clinic Number of Compounds in Phase I Phase II Phase III each Phase ASCO 2008 13 6 3 ASCO 2007 9 4 4 8

  9. Slide 9: Pfizer Oncology Clinical Portfolio

    Pfizer Oncology Clinical Portfolio TSP-1 (CVX-045)* Platform Key Ang-2 Ant Anti-Angiogenesis (CVX-060)* Transitions Since ASCO 2007 Signal Transduction ALK1 mAb (PF-3446962) Immunotherapy sVEGFR (PF-337,210) Cytotoxic/ mRTK Potentiators P-Cad mAb (SU-14,813) (PF-3, 732,010) Pan-ErbB FAK (PF-00299804

  10. Slide 10: Recent Oncology Licensing and Acquisitions

    Recent Oncology Licensing and Acquisitions Company/Compound Value to Pfizer Portfolio Avant – license Novel vaccine in Phase IIb/III for GBM CDX-110 (EGFRvIII vaccine) High unmet medical need Serenex – acquisition q Phase I, novel mechanism SNX-5422 (Hsp90 inhibitor) Complementary to portfolio CovX

  11. Slide 11: ASCO 2008: Abstracts on Pfizer Products

    ASCO 2008: Abstracts on Pfizer Products 2006 2007 2008 Anti-Angiogenesis Portfolio Sutent (mRTK Inhibitor) 17 33 273 Axitinib (VEGFR Inhibitor) 1 5 4 CP-868,596 (PDGFR Inhibitor) 1 1 SU-14,813 (mRTK Inhibitor) 1 1 CVX-045 (TSP-1) 1 Immunotherapy CDX-110 (EGFRvIII vaccine) 1 CP 675 206 (CTLA4 IInhibi

  12. Slide 12: Sutent: Established mRCC Market Leader

    Sutent: Established mRCC Market Leader mRCC Patient Share – 1st Line WW Sales by QTR US 59% $200 $180 France 74% $160 $140 Millions s $120 Germany 63% $100 $80 $60 Spain 63% $40 $20 Italy 51% $0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 UK 37% 2006 2007 2008 Sources: US share = ImpactRx (April ’08 data; N=153);

  13. Slide 13: Sunitinib (Sutent) Phase III Trials

    Sunitinib (Sutent) Phase III Trials 1st Line 2nd Line Adjuvant Metastatic Metastatic Breast cancer 2 2 NSCLC 1 GU 2(RCC) 1(HRPC*) CRC 1 Other GI 1(HCC*) 1(NET) *To be initiated in 2008; all others are ongoing 13

  14. Slide 14: Recent Phase III Starts

    Recent Phase III Starts Phase III Starts Since ASCO 2007 Sutent First line CRC Sutent Second line NSCLC Sutent Adjuvant RCC Axitinib Pancreatic cancer CP-751,871 First line NSCLC CP-751,871 Refractory NSCLC Phase III Trials Expected to be Initiated in 2008 Sutent First line HCC Sutent Second line mH

  15. Slide 15: Pfizer Programs in High Growth Segments

    Pfizer Programs in High Growth Segments Oncology Market Sales by Pfizer Programs Indication 2007 2007--2017 Phase II and Phase III 90,000 IGF-1R Pan- CTLA4 Sutent Axitinib mAb EGFRvIII ErbB mTKI PARP TLR9 mAb 75,000 Prostate 60,000 Prostate Breast Breast Cancer 45,000 Ovarian Colorectal Colorectal c

  16. Slide 16: NSCLC Development Program

    NSCLC Development Program Chuck Baum, M.D., Ph.D. CP-751,871 (IGF-1R mAb) Sutent Axitinib PF-00299804 (pan-ErbB)

  17. Slide 17: NSCLC Tumor Overview

    NSCLC Tumor Overview  The NSCLC Market remains attractive due to the lack of effective treatment options across all lines of therapy Cancer Global Mortality High Unmet Need Lung  Lung cancer accounts for 1.3 million deaths per year Stomach  5-year mean survival rate ~15% on a global Liver basis a

  18. Slide 18: Insulin-like Growth Factor Receptor (IGF-1R mAb)

    Insulin-like Growth Factor 1 Receptor (IGF-1R mAb) EGFR, HER-2, ER Receptor Crosstalk Growth, Survival, Metastasis 18

  19. Slide 19: Phase II: CP-751,871 with Paclitaxel/Carboplatin in 1st Line Advanced NSCLC

    Phase II: CP-751,871 with Paclitaxel/ Carboplatin in 1st Line Advanced NSCLC Study 1002 paclitaxel 200 mg/m2, carboplatin (AUC=6), n=97 Stage 1: CP-751,871 10 mg/kg Stage 2: CP-751,871 20 mg/kg 2:1 randomization N=150, 2 stages of 73 and 77 pts paclitaxel 200 mg/m2, n=53 carboplatin (AUC=6) 19

  20. Slide 20: Phase II: CP-751,871 in 1st Line NSCLC

    Phase II: CP-751,871 in 1st Line NSCLC Overall ORR: CP-751,871 + Chemo: 54% (52/97) [95% CI = 43-64%] Chemo: 41% (22/53) Response Rates by Histology • Highest RR in squamous cell carcinoma of 78% 100 Response Rate (%) N=29 N=69 N=39 80 • ORR 57% in i patients ti t with ith adenocarcinoma 60 40 • Inc

  21. Slide 21: Phase II: CP-751,871 in NSCLC

    Phase II: CP-751,871 in NSCLC Carboplatin/Paclitaxel Treatment-naïve Stage IIIB/IV NSCLC patients Carboplatin/Paclitaxel + CP-751,871 Dose (mg/kg) 0 10 20 Sample size (n) 50 46 53 Median PFS (months) 4.3 3.6 5.0 • 20 mg/kg is being taken forward to Phase III • Highest ORR in squamous histologies lin

  22. Slide 22: CP-751,871: NSCLC Summary

    CP-751,871: NSCLC Summary • We have initiated a Phase III program in NSCLC that will enroll more than 2,000 patients  The initial studies focus on the patients with highest levels of clinical benefit and also highest level of unmet need (non-adenocarcinoma) with subsequent studies focused on the br

  23. Slide 23: Multiple Pathways Associated with Anti-Angiogenic Agents

    Multiple Pathways Associated with Anti-Angiogenic Agents Tumor Cells ANTITUMOR and ANTIANGIOGENIC Effects Inhibition Endothelial Cells 23 23

  24. Slide 24: Phase III Program: Sunitinib (Sutent) in NSCLC (SUN 1087)

    Phase III Program: Sunitinib (Sutent) in NSCLC (SUN 1087) Phase II: Efficacy and Safety of Sutent SA Studied in Previously Treated NSCLC Patients Phase III Study Design N=63 100 R 80 A N Sutent + 60 erlotinib ne (%) Partial Responses by RECIST D 40 Stage IIIb O Stable Disease/Progressive Disease Cha

  25. Slide 25: Phase III: Axitinib in 1st Line NSCLC

    Phase III: Axitinib in 1st Line NSCLC Phase III Study Design Phase II: Overall Survival N=32 R 1.0 A N Axitinib + D Gem/Cis 0.8 Stage IIIb O or IV M 0.6 NSCLC I n=1000 Z A 0.4 T Placebo + I Gem/Cis 0.2 Median Overall Survival: 14.6 months O (95% CI: 107, undefined) N 0.0 0 5 10 15 20 Establish Effic

  26. Slide 26: Axitinib: Treatment-related AEs

    Axitinib: Treatment-related AEs (NSCLC single agent study) All grades Grade 3/4 n (%) n (%) Fatigue 23 (72) 7 (22) Anorexia 16 (50) 0 Diarrhea 14 (44) 1 (3) Hypertension 10 (31) 3 (9) Nausea 9 (28) 0 Hoarseness 9 (28) 0 Arthralgia 7 (22) 0 Dyspepsia 6 (19) 0 Epistaxis 2 (6) 0 Hemoptysis 2 (6) 0 Anem

  27. Slide 27: PF-00299804 (pan-ErbB): HER Biology

    PF-00299804 (pan-ErbB): HER Biology 27

  28. Slide 28: Pan-ErbB Inhibitor (PF-00299804)

    Pan-ErbB Inhibitor (PF-00299804)  PF-00299804 is an orally bioavailable, irreversible, small molecule inhibitor tyrosine kinases ErbB-1, ErbB-2 and ErbB-4  Preclinically, it has been shown to block the signaling in both wild type and mutant ErbB-1 (EGFR/HER-1) EGFR including forms which are resist

  29. Slide 29: Preliminary Activity and Safety Results of PF-00299804 in Phase I

    Preliminary Activity and Safety Results of PF-00299804 in Patients with Advanced NSCLC in Phase I Best Change per Target Lesion • Encouraging activity in heavily N=23 pre-treated patients with 250 advanced NSCLC after failure of eline (%) prior treatment with reversible 200 EGFR inhibitors Partial r

  30. Slide 30: Phase I Preliminary Activity Results of PF-00299804 in Advanced NSCLC

    Phase I Preliminary Activity Results of PF-00299804 in Patients with Advanced NSCLC Nov 2007 Jan 2008 Nov 2007 Jan 2008 Please note: these are results from one particular patient and may 30 not be representative of a larger population

  31. Slide 31: PF-00299804 Future Development Plan In NSCLC

    PF-00299804 Future Development Plan In NSCLC Clinical trials ongoing or planned in:  Refractory advanced NSCLC (after failure of EGFR TKI)  2nd / 3rd line advanced NSCLC (after failure of chemotherapy)  1st line advanced NSCLC (adenocarcinoma, non-smokers)  Combinations trials with chemotherapeu

  32. Slide 32: Pfizer's NSCLC Clinical Development Program

    Pfizer’s NSCLC Clinical Development Program Locally Recurrent/Metastatic (Stage IIIB Wet-IV) Phase III CP CP--751,871 +/vs carbo/pac (US) or gem/cis (exUS) 1st Line Phase III Axitinib +/vs gem/cis Ph Phase III CP CP--751,871 751 871 +/vs / erlotinib l ti ib (Global) (Gl b l) 2nd/3rd Line Phase III S

  33. Slide 33: Breast Cancer Development Program

    Breast Cancer Development Program Chuck Baum, M.D., Ph.D. Sutent

  34. Slide 34: Breast Cancer Tumor Overview

    Breast Cancer Tumor Overview  Breast cancer is a steadily growing market due to decreased mortality and effective treatments leading to longer durations of therapy. Cancer Global Mortality Key Takeaways Lung • 1 in 10 of all new cancers diagnosed Stomach worldwide, and is the most common cancer in

  35. Slide 35: Ongoing Phase III: Sutent + docetaxel in 1st line MBC (SUN 1064)

    Ongoing Phase III: Sutent + docetaxel in 1st line MBC (SUN 1064) Phase II Data of Docetaxel/Sutent Phase III Study Design Combination: Pilot Study R Number of Patients A Sutent + Best Response, N (%) (N=18; %) N Docetaxel D Patients with O Partial Response 13 (72) HER2- M Negati e Negative I Stable

  36. Slide 36: Ongoing Phase III: Sutent + paclitaxel in 1st line MBC (SUN 1094)

    Ongoing Phase III: Sutent + paclitaxel in 1st line MBC (SUN 1094) Encouraging Response Rate in Combination Phase III Study Design Therapy R Number of Patients A Sutent + Best Response, N (%) (N=78; %) N Paclitaxel Patients with D Advanced O 7 (33) Overall Response p Rate Breast M Cancer I N=740 Z A

  37. Slide 37: Ongoing Phase III: Sutent + capecitabine in 2nd/3rd line MBC (SUN 1099)

    Ongoing Phase III: Sutent + capecitabine in 2nd/3rd line MBC (SUN 1099) Phase I/II in advanced solid tumors: Phase III Study Design Percentage change from baseline in target tumor lesion size + capecitabine; N=66 R A Sutent + N Cape D Patients with O 2nd/3rd Line M Ad Advanced d I Breast Z Cancer A

  38. Slide 38: Pursuing Targets Important to Breast Cancer

    Pursuing Targets Important to Breast Cancer Additional Immune Sutent cell Mechanisms Under PF-00299804 Axitinib Investigation Pan-ErbB HSP 90 CHK1 cMET ErbB 1 CD40 Sutent FAK CDK4,6 CP-751,871 CP- CTLA4 IGF--1R IGF Sutent 38

  39. Slide 39: Pfizer's Breast Cancer Clinical Development Program

    Pfizer’s Breast Cancer Clinical Development Program Phase III Sutent + paclitaxel vs bevacizumab + paclitaxel Phase III Sutent +/vs docetaxel 1st Line Phase III Sutent vs capecitabine (1st/2nd line - China, Japan) Phase II CP CP--751,871 +/vs exemestane Phase II CP CP--751,871 +/vs docetaxel 2nd/3rd

  40. Slide 40: Glioblastoma Multiforme Development Program

    Glioblastoma Multiforme Development Program Chuck Baum Baum, M M.D., D PhPh.D. D CDX--110 CDX

  41. Slide 41: Glioblastoma Multiforme (GBM) Tumor Overview

    Glioblastoma Multiforme (GBM) Tumor Overview Cancer Global Mortality Key Takeaways Lung  GBM is the most common and Stomach most aggressive type of primary Liver brain tumor1, accounting for 50- Colon/rectum 60% of all primary brain tumors2 Breast Esophagus  The five year survival rate for all Cer

  42. Slide 42: Phase II Results: CDX-110 with TMZ in GBM Following Resection and Standard Radiation/TMZ

    Phase II Results: CDX-110 with TMZ in GBM Following Resection and Standard Radiation/TMZ ACTII Study Design Newly diagnosed EGFRvIII+ GBM after surgical resection and standard RT/TMZ ((N = 21)) CDX-110/KLH + GMCSF + TMZ* *Cohort 1: monthly TMZ 200 mg/m2 (N = 13) Cohort 2: continuous TMZ 100 mg/m2 (N

  43. Slide 43: Phase II Results: CDX-110 with TMZ in GBM Following Resection and Standard Radiation/TMZ

    Phase II Results: CDX-110 with TMZ in GBM Following Resection and Standard Radiation/TMZ ACTIII Study Design ACT II Data  * (PhII enrolling only) OS Cohort 1: 33.1 mo Newly Diagnosed CDX-110 + GBM Patients Temozolomide TTP Cohort 1: 23.7 mo • Gross total resection Maintenance • Documented Doc mente

  44. Slide 44: Genitourinary Cancer Development Program

    Genitourinary Cancer Development Program Craig Eagle, M.D. Sutent Axitinib

  45. Slide 45: Renal Cell Carcinoma Tumor Overview

    Renal Cell Carcinoma Tumor Overview  The RCC market continues to grow due to longer survival and effective treatments leading to longer durations of therapy Cancer Global Mortality Key Takeaways Lung Stomach  RCC incidence expected to Liver increase due to growth in elderly C l / Colon/rectum t po

  46. Slide 46: Sutent vs. Interferon in 1st Line mRCC Patients

    Sutent vs. Interferon in 1st Line mRCC Patients Study Design R A N Sutent D O Cross Over Stage IV, IV 1st M line Allowed to Sutent for I mRCC patients Patients Progressing Z N=750 on Interferon A T I Interferon O N 46 Motzer et al., N Engl J Med. 2007 Jan 11;356(2):115-24.

  47. Slide 47: Progression-Free Survival: Sutent vs Interferon in 1st Line mRCC Patients

    Progression-Free Survival: Sutent vs Interferon in 1st Line mRCC Patients Independent Central Review Sunitinib 1.0 Median PFS: 11 months 0.9 (95% CI: 10-12) Progression-Free Survivall Probability 0.8 IFN- Median PFS: 5 months 0.7 (95% CI: 4-6) 0.6 0.5 0.4 0.3 0.2 Hazard Ratio = 0.415 0.1 (95% CI: 0

  48. Slide 48: Sutent Extended Median Overall Survival >2 Years in Advanced Kidney Cancer

    Sutent Extended Median Overall Survival >2 Years in Patients with Advanced Kidney Cancer 48 Figlin et al., ASCO 2008

  49. Slide 49: Sutent Extended Median Overall Survival >2 Years in Advanced Kidney Cancer

    Sutent Extended Median Overall Survival >2 Years in Patients with Advanced Kidney Cancer (Wilcoxon) 49 Figlin et al., ASCO 2008

  50. Slide 50: Sutent Demonstrated a Doubling of OS in Sub-group Analysis

    Sutent Demonstrated a Doubling of OS in a Sub-group Analysis of Patients who Received 1st Line Therapy Only 50 Figlin et al., ASCO 2008

  51. Slide 51: Phase III Sutent 1st Line mRCC Treatment-Related Adverse Events

    Phase III Sutent 1st Line mRCC Treatment-Related Adverse Events Sunitinib (%) IFN- (%) Event All Grade Grade 3/4 All Grade Grade 3/4 Diarrhea 61 8* 15 1 Fatigue 54 11 52 13/<1 Nausea 52 4 35 1 Vomiting 31 4 12 1 Stomatitis 30 1 4 <1 Hypertension 30 12* 4 1 Hand-foot syndrome 29 8* 3 1 Ejection frac

  52. Slide 52: Sutent ASCO Results

    Sutent ASCO Results  Data showed that overall survival for patients treated with Sutent first line for mRCC, although not statistically significant, was more than two years, a great advance from the expected survival of about one year a few years ago  Sutent has consistently demonstrated improveme

  53. Slide 53: New Sutent Data at ASCO

    New Sutent Data at ASCO Data on new patient segments  Sutent showed antitumor activity and a comparable safety profile in mRCC patients with brain metastases and in non-nephrectomized patients Tolerability data  Advanced patients on Sutent for a long duration experienced a comparative increase in

  54. Slide 54: Axitinib Phase III Program in mRCC

    Axitinib Phase III Program in mRCC Phase II: Sequential Axitinib Therapy of Patients with Metastatic Clear Cell Renal Cell Cancer Phase III Study Design Refractory to Sunitinib and Sorafenib, Cytokines n=540 and Sorafenib, or Sorafenib Alone 40 Maximum Change in Target Lesion (%) R N=62 A N Axitinib

  55. Slide 55: Prostate Cancer Tumor Overview

    Prostate Cancer Tumor Overview  Prostate cancer represents an expanding and under-penetrated market opportunity with high unmet needs. Cancer Global Mortality Key Takeaways Lung • Prostate cancer is the most Stomach commonly diagnosed cancer in men Liver C l / Colon/rectum t • 1 in 6 men will devel

  56. Slide 56: Planned Phase III: Sutent in 2nd line Metastatic Hormone-refractory Prostate Cancer

    Planned Phase III: Sutent in 2nd line Metastatic Hormone-refractory Prostate Cancer (SUN 1120) Phase II: Sutent Combination Pilot Study Phase III Study Design Number of patients R BEST RESPONSE, N (%) (N=18; %) A Progressive Sutent + N 2nd line D prednisone PR response 5 (22) metastatic O hormone M

  57. Slide 57: Gastrointestinal Cancer Development Program

    Gastrointestinal Cancer Development Program Craig Eagle, M.D. Sutent Axitinib

  58. Slide 58: Hepatocellular Cancer a Significant Unmet Need

    Hepatocellular Cancer a Significant Unmet Need Cancer Global Mortality Key Takeaways Lung • HCC is the third leading cause of Stomach cancer death globally Liver Colon/rectum • Higher incidence and mortality particular in Asia Breast Esophagus • Limited treatment options Cervix uteri • Expected Mark

  59. Slide 59: Planned Phase III: Sutent vs. sorafenib in 1st Line Advanced HCC (SUN 1170)

    Planned Phase III: Sutent vs. sorafenib in 1st Line Advanced HCC (SUN 1170) Phase II: Single- Single-Agent Sunitinib Showed Activity in this Heavily Pretreated, Diverse Population Phase III Study Design of EU and Asian Patients R Number of Patients A Enrollment Criteria Best Response, N (%) (N=37; %

  60. Slide 60: Pancreatic Cancer Tumor Overview

    Pancreatic Cancer Tumor Overview Cancer Global Mortality Key Takeaways Lung  Pancreatic Cancer is the fourth leading Stomach cause of cancer death in the US and Liver Europe Colon/rectum  >60% of PC cases are diagnosed with Breast distant metastatic disease Esophagus  Median Overall Survival is C

  61. Slide 61: Phase III: Axitinib in 1st Line Advanced Pancreatic Cancer

    Phase III: Axitinib in 1st Line Advanced Pancreatic Cancer Phase II: Axitinib Activity in Advanced & Metastatic Pancreatic Cancer OS – Phase III Study Design All Randomized Patients N=103 R A N Axitinib + Patients with D gemcitabine 1.0 1st Line O Axitinib + gemcitabine (N=69) Advanced M Median OS:

  62. Slide 62: Pfizer Development Programs in GI

    Pfizer Development Programs in GI Phase III 1st line Sutent +/vs FOLFIRI CRC Phase II 1st line FOLFOX + Axitinib vs. FOLFOX + bevacizumab vs. FOLFOX + Axitinib + bevacizumab Phase II 2nd/3rd line FOLFOX or FOLFIRI + Axitinib vs. FOLFOX or FOLFIRI + bevacizumab HCC Phase III 1st line Sutent vs sorafe

  63. Slide 63: Concluding Remarks

    Concluding Remarks Alison Ayers World Wide Commercial Leader

  64. Slide 64: Pfizer Oncology Firsts

    Pfizer Oncology Firsts  Sutent – First oncology drug to be approved simultaneously for two indications  Leading in IGF-1R development with CP-751,871 – First in the clinic – First published data on IGF-1R activity – First IGF-1R to go into Phase III  First vaccine in development for treatment of

  65. Slide 65: Sutent Overview

    Sutent Overview ASCO Highlights: Development Program:  Sutent is associated with the  Phase III trials ongoing: longest median overall survival in – Metastatic breast cancer mRCC of any agent in the first-line setting to date – Advanced NSCLC – Metastatic colorectal cancer  Efficacy and safety of

  66. Slide 66: Axitinib Overview

    Axitinib Overview ASCO Highlights: Development Program:  Phase II trial showed activity in  Phase III trials ongoing: mRCC patients refractory to other – Pancreatic cancer anti-angiogenesis agents (sunitinib, sorafenib)  Phase III in initiation: – Second line RCC – First line NSCLC 66

  67. Slide 67: CP-751,871 (IGF-1R mAb) Overview

    CP-751,871 (IGF-1R mAb) Overview ASCO Highlights: Clinical Development:  Three oral presentations and one  Two Phase III NSCLC poster discussion demonstrating studies initiated; One planned efficacy and progression-free  Phase II program targets: survival in NSCLC treated with the combination CP-

  68. Slide 68: PF-00299804 (Pan-ErbB inhibitor) Overview

    PF-00299804 (Pan-ErbB inhibitor) Overview ASCO Highlights: Clinical Development:  Results of a Phase I clinical trial of  Phase II NSCLC PF-00299804 showed activity in heavily pre-treated NSCLC patients  Activity observed in patients refractory to erlotinib (Tarceva) 68

  69. Slide 69: CDX-110 Overview

    CDX-110 Overview ASCO Highlights: Clinical Development:  Phase II study, ACT II, showed 33  Pursue registration strategy in month median overall survival in GBM GBM in combination with temozolomide and radiation  Expand program to additional tumors based on p presence of  Unique cancer vaccine t

  70. Slide 70: Concluding Comments

    Concluding Comments  11 Phase III oncology starts since ASCO 2007  Strengthening of the GU franchise, especially RCC  Extensive BC development programs with data expected in 2009  Broad development programs in lung cancer  Leadership in IGF-1R development  Formation of the Pfizer Oncology Busi

  71. Slide 71: Q&A

    &A Phize r) Oncology om

Pfizer — ASCO 2008 Analyst Briefing on 6ix